Paul M. Eckles
Skadden, Arps, Slate, Meagher & Flom (New York)
Lawyer (Partner)
Paul M. Eckles is a partner in Skadden, Arps, Slate, Meagher & Flom’s Antitrust group in New York. He represents a wide variety of clients in antitrust, unfair business practices, consumer fraud and other complex litigation matters at both the trial and appellate court levels. Mr. Eckles also represents clients in connection with government investigations and provides general antitrust counseling. Mr. Eckles is representing CEMEX, Watson Pharmaceuticals, De Beers, Morgan Stanley, and Merrill Lynch in putative antitrust class actions. Other representations include, among others, successfully defending Activision Publishing, Inc. in an antitrust action challenging the purported tying of products; NewYork-Presbyterian Hospital in a putative antitrust class action brought by resident physicians; officers and directors of Stan Lee Media, Inc. in a securities class action and related commercial litigation; and International Paper Company in an antitrust class action alleging price-fixing.
Distinctions
Linked authors
John Adebiyi
Skadden, Arps, Slate, Meagher & Flom (London)
Steven Albertson
Skadden, Arps, Slate, Meagher & Flom (Washington DC)
James Anderson
Skadden, Arps, Slate, Meagher & Flom (London)
Iacovos Antoniou
Skadden, Arps, Slate, Meagher & Flom (Brussels)
Clifford H. Aronson
Skadden, Arps, Slate, Meagher & Flom (New York)
685 | Conferences
Articles
1428 Bulletin
252
Last week, in In re: Processed Egg Products Antitrust Litigation, the U.S. Court of Appeals for the Third Circuit issued a decision holding that purchasers of processed egg products have standing to seek damages from egg suppliers accused of price-fixing in violation of Section 1 of the Sherman (...)
85
On August 13, 2015, the U.S. Federal Trade Commission (FTC) issued formal guidance on Section 5 enforcement consisting of a general statement of principles to guide application of its authority to challenge “unfair methods of competition” under Section 5 of the FTC Act. While it is generally (...)
579
On September 8, 2014, the Federal Trade Commission (FTC) filed a federal antitrust complaint in the United States District Court for the Eastern District of Pennsylvania against defendants AbbVie, Abbott Laboratories, Unimed Pharmaceuticals, Besins Healthcare and Teva Pharmaceuticals alleging (...)
333
This article has been nominated for the 2012 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. On June 20, 2011, in Wal-Mart Stores, Inc. v. Dukes, the United States Supreme Court handed down its decision holding that discrimination claims on behalf of up (...)
179
On December 3, 2009, in In re Short Sale Antitrust Litigation (No. 08-0420-cv), the U.S. Court of Appeals for the Second Circuit affirmed the dismissal of a putative class action alleging collusion among certain financial institutions that serve as “prime brokers” in connection with short sale (...)
